The hidden intertwining pathways of metabolic and heart disease
How innovative imagery is driving early cardiometabolic diagnosis
SCIENTIFIC DIRECTOR @ UNIVERSITY OF COPENHAGEN
Challenges in Metagenomics
Currently, Dr Oluf Pedersen is professor and scientific leader at Novo Nordisk Foundation Centre for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen; he is Professor of Molecular Metabolism and Metabolic Genetics, Faculty of Health and Medical Sciences, University of Copenhagen. During 2007-2014 he was founder and director of Lundbeck Foundation Centre for Applied Medical Genomics in Personalised Disease Prediction, Prevention and Care. From 1989 to 2010 he was Chief Physician and Research Director at Steno Diabetes Centre and Hagedorn Research Institute, Copenhagen, a leading European and WHO-collaborative diabetes centre. Dr. Pedersen is a Danish Health Board-authorised Specialist of Internal Medicine (1987) and Specialist of Endocrinology (1987). He has published > 680 peer-reviewed scientific papers (h-index 98) with major innovation in clinical diabetes care (Steno-2 study), and molecular genetics and gut metagenomics in common metabolic disorders. He has received recognition as evidenced by 15 international and national personal awards; services as chairman or member on boards of scientific societies, biomedical councils, grant bodies and scientific journals.
CEO @ INTEGRATED BIOBANK OF LUXEMBOURG
Challenges in cardiometabolic disease biomarker discovery
After a Ph.D in Immunology, Catherine Larue began her career at Sanofi, Montpellier (France) in the cardiovascular R&D department and participated in the discovery of innovative biomarkers such as troponin I. She then joined Sanofi Diagnostics Pasteur, at Chaska MN (USA) for 3 years where she was responsible for Assay Development in the immunodiagnostic area. She completed an Executive MBA in 2003 and had worked for 7 years as a Director of Business Unit at Bio-Rad. After installing the biomarkers department in Genfit (Lille, France), she took over the CEO position of the Institute IBBL (Integrated Biobank of Luxembourg). Since Jan 2016, she is now the CEO of Luxembourg Institute of Health. She is an author of 87 publications and filed 13 patents. Her main expertise relies on cardio-metabolic biomedical research as well as on personalised medicine as she participated in a series of workshops leading to a “white paper” in June 2015. She served in standardisation committees at AACC and IFCC for 15 years; she also created and chaired the “Biomarkers Group” in the Competitiveness Bio-cluster (Medicen, Paris). She is currently serving as an expert for the European Commission (H2020 and IMI programmes).
BEN VAN OMMEN
@ NETHERLANDS METABOLOMICS CENTRE
Type 2 Diabetes: from Systems Biology
to Systems Change
The Netherlands Metabolomics Centre focuses on the development of metabolomics based technologies and instrumentation to address the current and future challenges in biology, biotechnology and biomedical research in order to improve personalised health and quality of life.
CHAIR OF NUTRITIONAL PHYSIOLOGY
@ TECHNICAL UNIVERSITY OF MUNICH
Precision Metabolic and Nutritional Phenotyping
Prof. Daniel (b. 1954) researches the basic principles of nutrient transport in mammals at genetic, structural and functional levels. She also studies the molecular basis of the adaptation of metabolic processes to changes in the intake of nutrients and non-nutritive ingredients of food as well as ageing processes. Prof. Daniel studied nutritional sciences at Justus Liebig University in Giessen. She received her doctorate in 1982 and qualified as a lecturer in Biochemistry of Human Nutrition in 1989. She has worked at the University of Glasgow and spent three years at the School of Medicine in Pittsburgh. She was appointed a full professor at the University of Giessen in 1992. Since 1998, she has held the Chair of Nutrition Physiology at TUM. Prof. Daniel is a member of the German Academy of Sciences (Leopoldina), various advisory bodies, supervisory boards and associations.